Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Cancer Res. 2015 Apr 1;75(13):2708–2715. doi: 10.1158/0008-5472.CAN-13-3209

Figure 1.

Figure 1

Kaplan-Meier curves for relapse-free survival of Acral and Non-CSD melanoma patients. A, Relapse-free survival time of acral melanoma patients with expression of both NUAK2 and p-Akt(S473) were dramatically shorter than acral melanoma patients with either NUAK2 or p-Akt(S473) alone (P = 0.002). B, Relapse-free survival time of Non-CSD melanoma patients with expression of both NUAK2 and p-Akt(S473) was not different from those of either NUAK2 or p-Akt(S473) alone (P = 0.721). Log rank test was used to detect survival time differences among three groups of patients: 1) Neither NUAK2 nor p-Akt(S473) positive; 2) Either NUAK2 or p-Akt(S473) positive; 3) Both NUAK2 and p-Akt(S473) positive. If we only compare groups 3 and 2 in acral melanomas, the p value is 0.003.